# 1. Financial Performance ## A. Key Figures * **Consolidated Total Income:** **₹2,692 Cr** Q3 (+12.1% YoY) · **₹8,081 Cr** 9M (+14.8% YoY) * **Profit Before Exceptional & Tax:** **₹854 Cr** Q3 (+17.6%) · **₹2,499 Cr** 9M (+21.8%) * **Profit After Tax:** **₹589 Cr** Q3 (-1.0% YoY) · **₹1,817 Cr** 9M (+18.8%) * **Gross Margin:** Improved YoY and QoQ in Q3 * **Balance Sheet (as of Dec 31):** **₹3,686 Cr** cash · **₹2,637 Cr** receivables · **₹3,667 Cr** inventory ## B. Revenue Growth * **Resilient Top-Line Expansion:** Solid double-digit revenue growth in both Q3 and 9M periods, supported by underlying demand and operational scale. * **Currency Impact Neutralized:** Constant currency growth of **6%** for 9M reflects real underlying volume and pricing momentum, with forex gains absorbed in other income. ## C. Profitability Trends * **Operating Leverage Strengthening:** Profit before exceptional items and tax showed robust growth, indicating improved core profitability despite a one-time ₹74 Cr employee benefit charge. * **Earnings Resilience:** Full-period PAT growth remained strong at nearly **19%** despite the exceptional item and tax volatility, underscoring earnings quality. ## D. Margin Drivers * **Favorable Mix Lifts Margins:** Gross margin expansion driven primarily by improved **Custom Synthesis (CS) contribution** over the 9-month period, despite quarterly product lumpiness. * **Short-Term Volatility Expected:** Management cautions against QoQ margin interpretation due to shipment timing variability; performance is best assessed on a longer-term trend basis. ## E. Balance Sheet Strength * **Healthy Liquidity Position:** Strong cash balance provides flexibility for strategic investments and downside protection. * **Asset Turnover Recovery Pathway:** Management targets restoration of gross asset turnover to **5–8x over 4–5 years**, supported by CS pipeline visibility and dedicated capex. --- # 2. Product & Segment Mix ## A. Key Figures * **Product Mix (Q3):** 43% generics · 57% custom synthesis * **Product Mix (9M):** 44% generics · 56% custom synthesis * **Nutraceuticals Revenue:** ₹214 Cr (Q3) · ₹706 Cr (9M) (+22.5% YoY) ## B. Generics Performance * **Stable Volume, Pressured Value:** Generics maintained stable performance with healthy volume growth in select products, though value growth remained constrained by persistent pricing pressures. * **Operational Strength:** Backward integration and process efficiencies supported delivery reliability, but limited growth was observed on the API generic side despite stable input costs. * **Market Recognition:** Analyst follow-up highlighted concern over subdued value realization despite volume gains, underscoring margin challenges in the segment. ## C. Custom Synthesis Mix * **Commercialization Momentum:** Multiple custom synthesis projects are nearing commercial scale within the next year, with three dedicated facilities set for launch from Q4 FY'27 across diverse chemistry initiatives. * **Strategic Diversification:** CS business is a diversified portfolio—not dependent on few products—with long-term visibility across clinical development, secondary sourcing, and lifecycle support. * **Margin Upside Expected:** Upcoming commercializations are anticipated to deliver significant positive impact on profitability, with management expressing strong confidence in growth potential. * **Peptide Leadership:** Company is actively manufacturing peptide fragments for global MNCs, leveraging expertise in protected amino acids and engaging across LPPS/SPPS platforms, including in high-interest areas like GLP-1. ## D. Nutraceuticals Growth * **Robust Segment Growth:** Nutraceuticals delivered strong revenue performance with **double-digit YoY growth**, supported by capacity expansion and strengthened market positioning. * **Strategic Expansion:** Celebrating 20 years in the business, Divi’s is scaling both protected amino acid and peptide fragment supply for commercial products, signaling long-term commitment to peptides. --- # 3. Manufacturing & Capacity ## A. Key Figures * **Capitalized Assets:** **₹313 Cr** Q3 FY26 · **₹776 Cr** 9M FY26 * **Capital Work in Progress:** **₹2,394 Cr** as of Dec 31, 2025 ## B. Facility Expansion * **Backward Integration Accelerating:** Unit 3 Phase 1 is operational, enabling shift of production from legacy units and supporting strategic repurposing of Unit 1 and Unit 2. * **GLP-1 Capacity Advancing:** Pilot plant commercialized and dedicated SPPS building completed, with validations underway for customer-specific large-scale peptide production. * **Demand-Driven Expansion Model:** Future capacity additions, including Phase 2 in Kakinada, remain under evaluation and will be triggered by customer demand and binding requirements. * **Scaling Protected Amino Acids:** Production scaled from validation-level to **multiple tens of tonnes** per amino acid, serving external fragment makers and feeding internal peptide pipelines. ## C. Production Readiness * **Flexible Commercial Readiness:** Multipurpose GMP blocks allow rapid commercial launch, though dedicated equipment may be needed for specific customer processes. * **End-to-End Peptide Capabilities:** Full-scale SPPS and LPPS platforms support clinical to commercial production across varying chain lengths (up to **18-mer**), based on innovator tech transfer. ## D. Automation Initiatives * **Next-Gen Chemistry Adoption:** Deployment of **mechanochemistry and electrochemistry** enables low-energy, continuous-flow reactions, enhancing process safety and sustainability. * **Automation Enhancing GMP & Safety:** Targeted automation in high-risk processes (e.g., azide chemistry) reduces human intervention, improving consistency and compliance. --- # 4. Supply Chain & Input Costs ## A. Key Figures * **Procurement:** **78%** domestic supplier base * Material Consumption: 36.3% of sales (Q3) · 38.5% of sales (9M) ## B. Backward Integration * **Strategic Expansion:** Unit 3 in Kakinada advancing backward integration through in-house production of starting materials and intermediates, supporting supply chain resilience. * **Resin R&D Initiative:** Company investing in internal peptide resin production to reduce **COGS**, where resin costs represent **nearly 40%** of expenses; currently in early R&D phase. * **China Diversification:** Active shift from Chinese procurement to domestic suppliers underway, aligning with "Make in India" and mitigating risks from **China’s April 1 removal of export tax rebates** on key materials. ## C. Procurement Strategy * **Stable Input Environment:** Raw material prices and logistics conditions remained stable, supported by diversified sourcing, backward integration, and strong vendor relationships. * **Proactive Risk Mitigation:** Supply chain resilience enhanced via multi-supplier qualification, **prudent inventory buffers**, and operational flexibility, with expectations of stable inputs over the next 6 months. --- # 5. Customer & Export Mix ## A. Key Figures * Export Revenue Mix: 89% of total sales (9M) * **Key Export Markets:** **73%** of exports to Europe & U.S. (H2) · **72%** of exports to Europe & U.S. (9M) ## B. Export Dependence * **High Export Reliance:** Near-total dependence on international markets, with Europe and the U.S. representing the dominant share of export revenue. * **Stable Geographic Mix:** Export concentration remains consistent across periods, indicating stable demand from core Western markets. ## C. Capacity Utilization * **Moderate Utilization with Upside:** Current capacity utilization ranges from **70% to 85%**, varying by segment and shipment cycle. * **Pipeline Validation Activity:** Several custom synthesis products in validation phase, signaling near-term commercial readiness and potential volume ramp. --- # 6. Regulatory & Approval Risks ## A. Client Approvals & Regulatory Progress * **Strategic Differentiation:** Divi's is leveraging its **strong EHS, sustainability, and compliance track record** to win CDMO partnerships with global innovators. * **Regulatory Confidence:** Successful **B. S. FDA CGMP inspection** at Choutuppal Unit 1 reinforces high-quality standards and de-risks client approval pathways. * **Commercialization Timeline:** Regulatory approvals remain the critical gating factor, with commercial volumes expected to be discussed **within one year post-approval**. * **Validation Momentum:** Product-specific validation is advancing across the pipeline—some completed, others ongoing—with immediate data and material release to clients upon completion. * **Client Approval Dependency:** Commercial supply from the dedicated facility is contingent on **formal client clearance**, not just regulatory or internal readiness. ## B. Inspection Timelines * **Inspection Uncertainty:** Despite recent agency inspections, potential **pre- or product-specific inspections** may still be triggered, depending on **customer filing regions** and regulatory discretion. ## C. FTA & External Dynamics * **India-EU FTA:** Management views the agreement as too nascent to evaluate tangible opportunities at this stage. * **China Supply Shift:** Reduction in Chinese tax rebates and export incentives suggests tightening supply conditions, potentially benefiting compliant global suppliers like Divi's—though impact remains uncertain amid macro volatility. --- # 7. Guidance & Outlook ## A. Key Figures * **Capex (FY '26):** **₹1,500 Cr** (H1) · **₹1,900 Cr** (revised full-year guidance) ## B. Growth Trajectory * **Resilient Growth Outlook:** Management reaffirms **double-digit growth trajectory** despite genericization of a key late-life-cycle product, underpinned by a balanced pipeline with new launches in Phase II/III. * **Pipeline Diversification:** Strategic expansion beyond GLP-1s into high-potential areas like **psoriasis**, with active projects in Phase I and II across multiple therapeutic areas. * **Revenue Ramp-Up Catalyst:** Near-term revenue acceleration expected as **fragment supply validation concludes** and newer products enter commercialization. ## C. Capex Plan * **Capex Moderation:** Revised FY '26 capex guidance to **₹1,900 Cr** from ₹2,000 Cr, with spending concentrated on Unit 1 and Unit 3; Custom Synthesis project excluded from outlook. * **Spending Discipline:** Full-year investment expected to align with **historical trends**, reflecting calibrated execution amid evolving project timelines. ## D. Commercialization Timeline * **2027 Commercial Launch Target:** All three dedicated Custom Synthesis projects target commercialization by **2027**, contingent on customer approvals and regulatory inspections. * **Volume Ramp-Up Timing:** Commercial volumes for CS segment molecules likely in **Q3 or Q4 2027**, potentially preceded by innovator inventory buildup post-approval.